Detalhe da pesquisa
1.
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Nature
; 627(8004): 646-655, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418879
2.
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Nature
; 627(8005): E11, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38480897
3.
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Nature
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38816613
4.
LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8+ T Cells.
J Immunol
; 203(4): 1076-1087, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31253728
5.
Correction: LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8+ T Cells.
J Immunol
; 203(7): 2023-2024, 2019 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31471523
6.
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
Cell Rep Med
; 5(2): 101393, 2024 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38280376